Clinical Evidence: The TRIUMPH Programme The clinical development of retatrutide is being tracked through the TRIUMPH programme, a series of global Phase 3 trials designed to secure regulatory approval across multiple indications, including chronic weight management, type 2 diabetes, and related comorbidities
Then, in September, the Trump Administration launched a crackdown on deceptive direct-to-consumer drug advertising, resulting in the FDA publishing over 55 warning letters to online sellers of compounded versions of GLP-1 medications that called for the removal of false and misleading promotional statements, claims of clinically proven weight-loss treatments, and using the words FDA-approved in advertising copy
If you are interested in whether GLP-1 could be part of your plan, the next step is to schedule a consultation at Forever Weight Loss Clinic
Semaglutide has also shown benefits for people living with chronic kidney disease and congestive heart failure